Primary record
(1R,3aS,3bR,7E,9aR,9bS,11aS)-11a-Ethyl-1-ethynyl-7-(hydroxyimino)-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[a]phenanthren-1-yl acetate
- 库存
- 8,382 克
- 纯度
- 98.3 %
- CAS
- 35189-28-7
化合物标识与属性
- CAS
- 35189-28-7
- PubChem CID
- 6540478
- SMILES
- CC[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)OC(=O)C)CCC4=C/C(=N/O)/CC[C@H]34
- Canonical SMILES
- C#C[C@]1(OC(C)=O)CC[C@H]2[C@@H]3CCC4=C/C(=N/O)CC[C@@H]4[C@H]3CC[C@@]21CC
名称与同义词
- NORGESTIMATE
- Dexnorgestrel acetime
- Norgestimato
- Norgestimatum
- Ortho-Prefest
- anti-Norgestimate
- dexnorgestrel
- Norgestimate, E-
- 35189-28-7
- Ortho Tri-Cyclen
- Mixture Name
- Ortho-Cyclen
- syn-Norgestimate
- Ortho Cyclen-21
- Ortho Cyclen-28
- norgestrel oxime acetate
- Norgestimatum [INN-Latin]
- Norgestimato [INN-Spanish]
- NKX8DN6TY9
- Norgestimate-[d3]
- Norgestimate (USP/INN)
- UNII-NKX8DN6TY9
- C23H31NO3
- DTXSID1046922
- Norgestimate-d3 (major)
- RefChem:927916
- Norgestimate [USAN:INN:BAN]
- ORF 10131
- ORF-10131
- RWJ 10131
- D09QZI
- UNII-C291HFX4DY
- C291HFX4DY
- RWJ-10131
- SCHEMBL38317
- DTXCID9026922
- CHEBI:50815
- KIQQMECNKUGGKA-NMYWJIRASA-N
- AC1O712U
- GTPL7091
- Norgestimate [USAN:BAN:INN]
- orb1299730
- CHEMBL1200934
- ERK5-3D03
- HSDB 7898
- Norgestimate, >=97% (HPLC)
- Norgestimate for system suitability
- NSC-759159
- MSK10044
- EINECS 244-046-1
- Norgestimate [USAN:USP:INN:BAN]
- Tox21_112811
- AC-655
- C23-H31-N-O3
- EBC-26821
- MFCD00867874
- NCGC00181353-01
- D 138
- AKOS015917555
- Tox21_112811_1
- ACN-037301
- BLP-011616
- CID6540478
- DB00957
- [(3E,8R,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-3-hydroxyimino-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl] acetate
- CID:6540478
- D-138
- NCGC00344561-01
- AJ-47459
- AN-15646
- AS-12305
- BC206215
- BC687005
- LS-62080
- SID:53787279
- AB0011687
- CAS-35189-28-7
- J968.604E
- ST2402017
- NS00001983
- (+)-13-Ethyl-17-hydroxy-18,19-dinor-17alpha-pregn-4-en-20-yn-3-one oxime acetate (ester)
- D05209
- F85625
- 107382-52-5
- 20799-27-3
- 351N287
- A822635
- C017576
- (17alpha)-17-(Acetyloxy)-13-ethyl-18,19-dinorpregn-4-en-20-yn-3-one 3-oxime
- d-13beta-Ethyl-17alpha-ethynyl-17beta-acetoxygon-4-en-3-one oxime
- I14-9729
- Q7051181
- d-13-beta-Ethyl-17-alpha-ethynyl-17-beta-acetoxygon-4-en-3-one oxime
- (17-alpha)-17-(Acetyloxy)-13-ethyl-18,19-dinorpregn-4-en-20-yn-3-one 3-oxime
- (3E)-17alpha-ethynyl-3-(hydroxyimino)-18a-homoestr-4-en-17beta-yl acetate
- ORF-10131, D-138, AC-655, RWJ-10131
- 18,19-Dinorpregn-4-en-20-yn-3-one, 17-(acetyloxy)-13-ethyl-, 3-oxime, (17.alpha.)-
- 18,19-Dinorpregn-4-en-20-yn-3-one, 17-(acetyloxy)-13-ethyl-, 3-oxime, (3E,17alpha)-
- D-13beta-Ethyl-17alpha-ethynyl-17beta-acetoxygon-4-en-3-oneoxime
- (+-)-13-ethyl-17alpha-hydroxy-18,19-dinor-pregn-4-en-20-yn-3-one oxime acetate
- (1)-13-Ethyl-17alpha-hydroxy-18,19-dinor-pregn-4-en-20-yn-3-one oxime acetate
- (3E,17R)-17-Acetoxy-13-ethyl-18,19-dinorpregna-4-ene-20-yne-3-oneoxime
- 13-Ethyl-17-hydroxy-18,19-dinor-17?-pregn-4-en-20-yn-3-one oxime acetate (ester)
- 18,19-Dinorpregn-4-en-20-yn-3-one, 17-(acetyloxy)-13-ethyl-, 3-oxime, (17-alpha)-
- (1R,3aS,3bR,7E,9aR,9bS,11aS)-11a-ethyl-1-ethynyl-7-(hydroxyimino)-1H,2H,3H,3aH,3bH,4H,5H,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-1-yl acetate
- (1R,3aS,3bR,7E,9aR,9bS,11aS)-11a-Ethyl-1-ethynyl-7-(hydroxyimino)-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[a]phenanthren-1-yl acetate
- (1S,2R,5E,10R,11S,14R,15S)-15-ethyl-14-ethynyl-5-(hydroxyimino)tetracyclo(8.7.0.0^(2,7).0^(11,15))heptadec-6-en-14-yl acetate
- (1S,2R,5E,10R,11S,14R,15S)-15-ethyl-14-ethynyl-5-(hydroxyimino)tetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-6-en-14-yl acetate
- 18,19-Dinor-17-pregn-4-en-20-yn-3-one, 17-(acetyloxy)-13-ethyl-, oxime, (17alpha)- (+)-
- 18,19-Dinor-17-pregn-4-en-20-yn-3-one, 17-(acetyloxy)-13-ethyl-, oxime, (17alpha)-(+)-
- 18,19-Dinor-17alpha-pregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-, oxime, acetate (ester), (+-)
- 18,19-DINORPREGN-4-EN-20-YN-3-ONE, 17-(ACETYLOXY)-13-ETHYL-, 3-OXIME, (3E,17.ALPHA.)-